Jennifer Kayden Lee sold $8.9M of RYTM
EVP, Head of North America at RHYTHM PHARMACEUTICALS, INC.. 75,834 shares at an average of $117.38, traded Aug 13, 2026, filed Aug 14, 2026.
Score components
- +15RoleOfficer
- +25Trade size$8.9M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001649904-26-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | MOption exercise Common Stock10b5-1 | +35,000 | $24.29 | $850k | 54,233 | Aug 14, 2026 |
| Aug 13, 2026 | MOption exercise Common Stock10b5-1 | +21,601 | $6.80 | $147k | 75,834 | Aug 14, 2026 |
| Aug 13, 2026 | SOpen-market sale Common Stock10b5-1 | -75,834 | $117.38 | $8.9M | 0 | Aug 14, 2026 |
| Aug 13, 2026 | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -35,000 | $0.00 | $0 | 36,283 | Aug 14, 2026 |
| Aug 13, 2026 | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -21,601 | $0.00 | $0 | 0 | Aug 14, 2026 |
Related signals
Other insiders at RHYTHM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | RHYTHM PHARMACEUTICALS, INC. | David P Meeker President and CEO | $5.1M 50,000 shares | -17% | |
| 30Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $6.6M 62,774 shares | -36% | |
| 54Moderate | RHYTHM PHARMACEUTICALS, INC. | Alastair Garfield Chief Scientific Officer | $913k 7,763 shares | -77% | |
| 20Weak | RHYTHM PHARMACEUTICALS, INC. | Joseph Shulman Chief Technical Officer | $608k 5,079 shares | -24% | |
| 40Moderate | RHYTHM PHARMACEUTICALS, INC. | Yann Mazabraud EVP, Head of International | $6.6M 57,000 shares | -51% | |
| 25Weak | RHYTHM PHARMACEUTICALS, INC. | Lynn A. Tetrault director | $3.7M 37,000 shares | -84% | |
| 37Weak | RYTMsell RHYTHM PHARMACEUTICALS, INC. | Christopher Paul German Corporate Controller & CAO | $428k 4,643 shares | -100% | |
| 38Weak | RYTMsell RHYTHM PHARMACEUTICALS, INC. | Christopher Paul German Corporate Controller & CAO | $503k 5,614 shares | -97% | |
| 24Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $806k 7,954 shares | -7% | |
| 23Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $709k 7,071 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.